Literature DB >> 21523403

Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy.

C Elsing1, S Ernst, N Kayali, W Stremmel, S Harenberg.   

Abstract

AIM: Several new biomarkers, such as lipopolysaccharide binding protein (LBP) and interleukin-6 (IL-6), have the potential to determine the severity and outcome of infectious diseases. LBP and IL-6 serum levels have not been reported in patients with gastrointestinal infections. The aim of this study was to compare established markers of infection with new markers, such as LBP and IL-6, in patients with acute gastrointestinal infections
METHOD: LBP, C-reactive protein (CRP), white blood cell count (WBC) and IL-6 serum levels were determined in patients with acute viral or bacterial (positive stool cultures) gastroenteritis. The final diagnosis and empiric antibiotic use were recorded. In total, medical data on 88 patients with acute gastroenteritis (22 bacterial, 66 viral or nonspecific) were analyzed.
RESULTS: LBP and CRP levels were significantly increased in patients with acute bacterial gastroenteritis [28.5 ± 16.5 vs. 15.2 ± 11.5 μg/mL (p < 0.05) and 10.4 ± 9.6 vs. 3.8 ± 5.5 mg/dL (p < 0.001), respectively]. LBP at a cut-off value of 14.6 μg/mL and CRP at a cut-off value of 1.7 mg/dL distinguished between bacterial and non-bacterial gastrointestinal infection (receiver operator characteristic analysis). Empiric antibiotic therapy was initiated in 82% of patients with bacterial gastroenteritis and in 27% of patients with viral gastroenteritis.
CONCLUSION: The use of the cut-off values for LBP and CRP determined here would have avoided unnecessary antibiotic therapy in 14 and 11%, of patients respectively. CRP and LBP appear to be superior to IL-6 and WBC as diagnostic markers of bacterial gastrointestinal infection. Cut-off values may be a useful tool to support clinical decision-making on whether or not to initiate empiric antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523403     DOI: 10.1007/s15010-011-0117-5

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

1.  Increased circulating levels of lipopolysaccharide binding protein in children with Escherichia coli O157:H7 hemorrhagic colitis and hemolytic uremic syndrome.

Authors:  F Proulx; E Seidman; M M Mariscalco; K Lee; S Caroll
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia.

Authors:  Mar Masiá; Félix Gutiérrez; Belén Llorca; Juan Carlos Navarro; Carlos Mirete; Sergio Padilla; Ildefonso Hernández; Emilio Flores
Journal:  Clin Chem       Date:  2004-09       Impact factor: 8.327

3.  Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults.

Authors:  L J Goodman; G M Trenholme; R L Kaplan; J Segreti; D Hines; R Petrak; J A Nelson; K W Mayer; W Landau; G W Parkhurst
Journal:  Arch Intern Med       Date:  1990-03

Review 4.  A novel acute-phase marker: lipopolysaccharide binding protein (LBP).

Authors:  R R Schumann; J Zweigner
Journal:  Clin Chem Lab Med       Date:  1999-03       Impact factor: 3.694

5.  Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections.

Authors:  A R Franz; G Steinbach; M Kron; F Pohlandt
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

Review 6.  Initial responses to endotoxins and Gram-negative bacteria.

Authors:  Didier Heumann; Thierry Roger
Journal:  Clin Chim Acta       Date:  2002-09       Impact factor: 3.786

7.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

Authors:  T Calandra; J Gerain; D Heumann; J D Baumgartner; M P Glauser
Journal:  Am J Med       Date:  1991-07       Impact factor: 4.965

8.  Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein.

Authors:  Maja Pavcnik-Arnol; Sergej Hojker; Metka Derganc
Journal:  Intensive Care Med       Date:  2004-05-04       Impact factor: 17.440

Review 9.  Antibiotic consumption and link to resistance.

Authors:  H Goossens
Journal:  Clin Microbiol Infect       Date:  2009-04       Impact factor: 8.067

10.  Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study.

Authors:  Shahin Gaïni; Ole Graesbøll Koldkjaer; Court Pedersen; Svend Stenvang Pedersen
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  11 in total

1.  Markers of systemic exposures to products of intestinal bacteria in a dietary intervention study.

Authors:  Faith I Umoh; Ikuko Kato; Jianwei Ren; Phillip L Wachowiak; Mack T Ruffin; D Kim Turgeon; Ananda Sen; Dean E Brenner; Zora Djuric
Journal:  Eur J Nutr       Date:  2015-04-24       Impact factor: 5.614

Review 2.  Evaluation of molecular and genetic predisposing parameters at diverticular disease of the colon.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Athina Tousia; George Chatzopoulos; Anastasia Gkiala; Athanasios Syllaios; Maximos Frountzas; Pantelis Vassiliu; Georgios E Theodoropoulos; Evangelos Felekouras
Journal:  Int J Colorectal Dis       Date:  2021-01-07       Impact factor: 2.571

Review 3.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

4.  Biomarkers of inflammation - LBP and TLR- predict progression of knee osteoarthritis in the DOXY clinical trial.

Authors:  Z Y Huang; E Perry; J L Huebner; B Katz; Y-J Li; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2018-08-23       Impact factor: 6.576

5.  Serum C-reactive protein (CRP) levels in young adults can be used to discriminate between inflammatory and non-inflammatory diarrhea.

Authors:  Dong Hwan Kim; Sun Hyung Kang; Woo Suk Jeong; Hee Seok Moon; Eaum Seok Lee; Seok Hyun Kim; Jae Kyu Sung; Byung Seok Lee; Hyun Yong Jeong
Journal:  Dig Dis Sci       Date:  2012-08-29       Impact factor: 3.199

6.  LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients.

Authors:  Odin Goovaerts; Wim Jennes; Marguerite Massinga-Loembé; Ann Ceulemans; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

Review 7.  Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.

Authors:  Anokhi J Kapasi; Sabine Dittrich; Iveth J González; Timothy C Rodwell
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

8.  Antibiotic Treatments for Clostridium difficile Infection Are Associated with Distinct Bacterial and Fungal Community Structures.

Authors:  Regina Lamendella; Justin R Wright; Jada Hackman; Christopher McLimans; David R Toole; William Bernard Rubio; Rebecca Drucker; Hoi Tong Wong; Kate Sabey; John P Hegarty; David B Stewart
Journal:  mSphere       Date:  2018-01-10       Impact factor: 4.389

9.  Effects of Puerariae Radix Extract on Endotoxin Receptors and TNF-α Expression Induced by Gut-Derived Endotoxin in Chronic Alcoholic Liver Injury.

Authors:  Jing-Hua Peng; Tuan Cui; Zhao-Lin Sun; Fu Huang; Liang Chen; Lin Xu; Qin Feng; Yi-Yang Hu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-21       Impact factor: 2.629

10.  A novel marker procalcitonin may help stem the antibiotic overuse in emergency setting.

Authors:  Kamalpreet Kaur; Rajiv Mahajan; Aparna Tanwar
Journal:  Int J Appl Basic Med Res       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.